Th1 epitope selection for clinically effective cancer vaccines.
about
Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.Moving forward with human papillomavirus immunotherapies.Cationic domains in particle-forming and assembly-deficient HBV core antigens capture mammalian RNA that stimulates Th1-biased antibody responses by DNA vaccination
P2860
Th1 epitope selection for clinically effective cancer vaccines.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Th1 epitope selection for clinically effective cancer vaccines.
@en
Th1 epitope selection for clinically effective cancer vaccines.
@nl
type
label
Th1 epitope selection for clinically effective cancer vaccines.
@en
Th1 epitope selection for clinically effective cancer vaccines.
@nl
prefLabel
Th1 epitope selection for clinically effective cancer vaccines.
@en
Th1 epitope selection for clinically effective cancer vaccines.
@nl
P2093
P2860
P1433
P1476
Th1 epitope selection for clinically effective cancer vaccines.
@en
P2093
Denise L Cecil
Mary L Disis
William C Watt
P2860
P304
P356
10.4161/21624011.2014.954971
P577
2014-10-01T00:00:00Z